- Letter
- Published:
Human hepatitis B vaccine from recombinant yeast
- William J. McAleer1,
- Eugene B. Buynak1,
- Robert Z. Maigetter1,
- D. Eugene Wampler1,
- William J. Miller1 &
- …
- Maurice R. Hilleman1
Naturevolume 307, pages178–180 (1984)Cite this article
6053Accesses
16Altmetric
Abstract
The worldwide importance of human hepatitis B virus infection and the toll it takes in chronic liver disease, cirrhosis and hepatocarcinoma, make it imperative that a vaccine be developed for worldwide application1. Human hepatitis B vaccines2–6 are presently prepared using hepatitis B surface antigen (HBsAg) that is purified from the plasma of human carriers of hepatitis B virus infection. The preparation of hepatitis B vaccine from a human source is restricted by the available supply of infected human plasma and by the need to apply stringent processes that purify the antigen and render it free of infectious hepatitis B virus and other possible living agents that might be present in the plasma. Joint efforts between our laboratories and those of Drs W. Rutter and B. Hall led to the preparation of vectors carrying the DNA sequence7,8 for HBsAg and antigen expression in the yeastSaccharomyces cerevisiae9. Here we describe the development of hepatitis B vaccine of yeast cell origin. HBsAg of subtype adw was produced in recombinant yeast cell culture, and the purified antigen in alum formulation stimulated production of antibody in mice, grivet monkeys and chimpanzees. Vaccinated chimpanzees were totally protected when challenged intravenously with either homologous or heterologous subtype adr and ayw virus of human serum source. This is the first example of a vaccine produced from recombinant cells which is effective against a human viral infection.
This is a preview of subscription content,access via your institution
Access options
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deinhardt, F. & Gust, I. D.Bull. Wld Hlth Org.60, 661–691 (1982).
Hilleman, M. R.et al.Viral Hepatitis (eds Vyas, G. N., Cohen, S. N. & Schmid, R.) 525–537 (The Franklin Institute Press, Philadelphia, 1978).
Hilleman, M. R.et al. inViral Hepatitis 1981 int. Symp. (eds Szmuness, W., Alter, H. & Maynard, J.) 385–397 (The Franklin Institute Press, Philadelphia, 1982).
Buynak, E. B.et al.J. Am. med. Ass.235, 2832–2834 (1976).
Adamowicz, P.et al. inINSERM Symp. No. 18 (eds Maupas, P. & Guesry, P.) 37–49 (Elsevier, Amsterdam, 1981).
Coutinho, R. A.et al.Br. med. J.286, 1305–1308 (1983).
Valenzuela, P.et al.Nature280, 815–819 (1979).
Edman, J. C., Hallewell, R. A., Valenzuela, P., Goodman, H. M. & Rutter, W. J.Nature291, 503–506 (1981).
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. & Hall, B. D.Nature298, 347–350 (1982).
Alexander, J. J., Bey, E. M., Geddes, E. W. & Lecatsas, G.S. Afr. med. J.50, 2124–2128 (1976).
Barin, F., Maupas, P., Coursaget, P., Goudeau, A. & Chiron, J. P. inINSERM Symp. No. 18 (eds Maupas, P. & Guesry, P.) 263–266 (Elsevier, Amsterdam, 1981).
Moriarty, A. M., Hoyer, B. H., Shih, J. W-K., Gerin, J. L. & Hamer, D. H.Proc. natn. Acad. Sci. U.S.A.78, 2606–2610 (1981).
Dubois, M. F., Pourcel, C., Rousset, S., Chany, C. & Tiollais, P.Proc. natn. Acad. Sci. U.S.A.77, 4549–4553 (1980).
Burrell, J. C., Mackay, P., Greenway, P. J., Hofschneider, P. H. & Murray, K.Nature279, 43–47 (1979).
Lerner, R. A.et al.Proc. natn. Acad. Sci. U.S.A.78, 3403–3407 (1981).
Dreesman, G. R.et al.Nature295, 158–160 (1982).
Bhatnagar, P. K.et al.Proc. natn. Acad. Sci. U.S.A.79, 4400–4404 (1982).
Prince, A. M., Ikram, H. & Hopp, T. P.Proc. natn. Acad. Sci. U.S.A.79, 579–582 (1982).
Gerin, J. L.et al.Proc. natn. Acad. Sci. U.S.A.80, 2365–2369 (1983).
Smith, G. L., Mackett, M. & Moss, B.Nature302, 490–495 (1983).
Miyanohara, A.et al.Proc. natn. Acad. Sci. U.S.A.80, 1–5 (1983).
Hitzeman, R. A.et al.Nucleic Acids Res.11, 2745–2763 (1983).
Deters, D., Muller, U. & Homberger, H.Analyt. Biochem.70, 263–267 (1976).
Ono, Y.et al.Nucleic Acids Res.11, 1747–1757 (1983).
Gerety, R. J., Tabor, E., Purcell, R. H. & Tyeryar, F. J.J. infect. Dis.140, 642–648 (1979).
Szmuness, W., Stevens, C. E., Zang, E. A., Harley, E. J. & Kellner, A.Hepatology1, 377–385 (1981).
Francis, D. P.et al.Ann. intern. Med.97, 362–366 (1982).
Szmuness, W.et al.New Engl. J. Med.307, 1481–1486 (1982).
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R.J. biol. Chem.193, 265–275 (1951).
Laemmli, U. K.Nature227, 680–685 (1970).
Morrissey, J. H.Analyt. Biochem.117, 307–310 (1981).
Author information
Authors and Affiliations
Division of Virus and Cell Biology Research, Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, 19486, USA
William J. McAleer, Eugene B. Buynak, Robert Z. Maigetter, D. Eugene Wampler, William J. Miller & Maurice R. Hilleman
- William J. McAleer
You can also search for this author inPubMed Google Scholar
- Eugene B. Buynak
You can also search for this author inPubMed Google Scholar
- Robert Z. Maigetter
You can also search for this author inPubMed Google Scholar
- D. Eugene Wampler
You can also search for this author inPubMed Google Scholar
- William J. Miller
You can also search for this author inPubMed Google Scholar
- Maurice R. Hilleman
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
McAleer, W., Buynak, E., Maigetter, R.et al. Human hepatitis B vaccine from recombinant yeast.Nature307, 178–180 (1984). https://doi.org/10.1038/307178a0
Received:
Accepted:
Issue Date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
Targeting aging and age-related diseases with vaccines
- Ruochen Wu
- Fei Sun
- Guang-Hui Liu
Nature Aging (2024)
Endotoxin-free gram-negative bacterium as a system for production and secretion of recombinant proteins
- Ehud Shahar
- Ken Emquies
- Itamar Yadid
Applied Microbiology and Biotechnology (2023)
Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus
- Neil C. Dalvie
- Joseph R. Brady
- J. Christopher Love
Microbial Cell Factories (2021)
Establishment of a yeast-based VLP platform for antigen presentation
- David Wetzel
- Theresa Rolf
- Michael Piontek
Microbial Cell Factories (2018)
Molecular evolution and genomics of hepatitis B virus subgenotype C2 strain predominant in the chronic patients in Bangladesh
- Modhusudon Shaha
- Sourav Chakraborty
- Md. Salimullah
VirusDisease (2018)